What is the translation of " DIFFERENCES IN SAFETY " in Swedish?

• skillnader i säkerhet
• skillnad i säkerhet

Examples of using Differences in safety in English and their translations into Swedish

No overall differences in safety and efficacy were observed for elderly patients.
Inga generella skillnader i säkerhet och effekt observerades för äldre patienter.

Erivedge in advanced basal cell carcinoma, approximately 40% of patients were≥ 65 years old and no overall differences in safety and efficacy were observed between these patients and younger patients.
var ungefär 40% av patienterna ≥ 65 år och ingen övergripande skillnad i säkerhet eller effekt observerades mellan dessa patienter och yngre patienter.

No overall differences in safety or effectiveness were observed between elderly
Inga generella skillnader i säkerhet eller effekt har observerats mellan äldre

There were no clinically relevant differences in safety between males(N=382) and females(N=139) in the FLAGS study.
Det fanns inga kliniskt relevanta skillnader i säkerhet mellan män(n=382) och kvinnor(n=139) i FLAGS-studien.

No differences in safety or efficacy were observed between elderly( 65 years) patients and younger patients.
Inga skillnader i säkerhet och effekt har observerats mellan äldre( 65 år) patienter och yngre patienter.

Special patient populations No differences in safety or efficacy were observed between elderly(≥ 65 years) patients and younger patients.
Speciella patientpopulationer Inga skillnader i säkerhet och effekt har observerats mellan äldre(≥ 65 år) patienter och yngre patienter.

No differences in safety or efficacy have been shown compared to adult women aged 18
Inga skillnader i säkerhet eller effekt har visats jämfört med vuxna kvinnor, 18 år gamla

In clinical studies no overall differences in safety or efficacy were observed between patients aged≥ 65 years and younger patients.
I kliniska studier observerades inga generella skillnader i säkerhet och effekt mellan patienter ≥ 65 år och yngre patienter.

No overall differences in safety were reported between elderly(≥ 65 years)
Ingen generella skillnader avseende säkerhet sågs mellan äldre(≥ 65 år)

No overall differences in safety or efficacy were observed between geriatric patients
Inga övergripande skillnader i säkerhet och effekt observerades mellan geriatriska patienter

No overall differences in safety or effectiveness were observed between these older patients
Inga totala skillnader i säkerhet eller effekt observerades mellan dessa äldre patienter

No overall differences in safety or efficacy were reported between elderly(≥65 years)
Ingen skillnad i säkerhet eller effekt rapporterades hos äldre(> 65 år)

No overall differences in safety or effectiveness were observed between these patients
Inga generella skillnader beträffande säkerhet eller effektivitet observerades mellan dessa patienter

No overall differences in safety or efficacy were reported between elderly(≥ 65 years)
Inga generella skillnader i säkerhet och effekt rapporterades mellan äldre(≥ 65 år)

No overall differences in safety or efficacy were observed between elderly(≥ 65 years old)
Inga övergripande skillnader i säkerhet och effekt observerades mellan äldre patienter(≥ 65 år)

No overall differences in safety or efficacy have been observed in patients<
Inga övergripande skillnader i säkerhet eller effekt har observerats hos patienter<

No overall differences in safety or effectiveness were observed between patients 65 years
Inga övergripande skillnader i säkerhet eller effektivitet observerades mellan patienter som var minst 65 år

No overall differences in safety or efficacy were observed in elderly patients(≥ 65 years of age)
Inga generella skillnader i säkerhet eller effekt har observerats hos äldre patienter(≥ 65 år)

No overall differences in safety or efficacy were observed between adolescent
Ingen övergripande skillnad i säkerhet eller effekt observerades mellan ungdomar

No overall differences in safety or efficacy have been observed between older
Inga generella skillnader i säkerhet eller effekt har observerats mellan äldre

No significant differences in safety and efficacy of Perjeta were observed between elderly patients aged 65 to 75 years and adult patients aged< 65 years.
Inga signifikanta skillnader i säkerhet och effekt för Perjeta observerades mellan äldre patienter mellan 65 och 75 år och vuxna patienter< 65 år.

No overall differences in safety were observed between the geriatric patients
Ingen övergripande skillnad i säkerhet observerades mellan gamla och unga patienter,

No overall differences in safety or efficacy were observed between older
Inga övergripande skillnader i säkerhet eller effekt sågs mellan äldre

No overall differences in safety or efficacy were observed between elderly(aged≥ 65 years) and younger patients(aged<
Inga övergripande skillnader i säkerhet eller effekt observerades mellan äldre(ålder ≥ 65 år)

No overall differences in safety or effectiveness were observed between these patients
Inga övergripande skillnader i säkerhet eller effekt observerades mellan dessa patienter

No overall differences in safety of Zurampic were observed in patients with mild
Inga övergripande skillnader i säkerhet för Zurampic har observerats hos patienter med lindrigt

No significant differences in safety or effectiveness were observed based on age,
Ingen signifikant skillnad i säkerhet eller effektivitet observerades med avseende på ålder,

In clinical studies, subgroup analyses based on age and gender did not indicate any difference in safety and efficacy in insulin glargine-treated patients compared to the entire study population.
I kliniska studier uppvisade subgruppanalyser med avseende på ålder och kön inga skillnader i säkerhet och effekt hos patienter behandlade med insulin glargin jämfört med den totala studiepopulationen.

No overall difference in safety or efficacy was observed between these patients
Inga generella skillnader i säkerhet och effekt observerades mellan dessa patienter

For myelodysplastic syndromes patients treated with lenalidomide, no overall difference in safety and efficacy was observed between patients aged over 65
För patienter med myelodysplastiskt syndrom som behandlas med lenalidomid sågs ingen övergripande skillnad i säkerhet och effekt mellan patienter som var äldre än 65 år